eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2020
vol. 6
 
Share:
Share:
abstract:
Letter to the Editor

Hepatitis C virus infection and atherosclerotic cardiovascular disease: recent knowledge, further insights

Dimitrios Ioannis Patoulias
1
,
Maria-Styliani Kalogirou
1

1.
Second Propedeutic Department of Internal Medicine, General Hospital “Hippokration”, Aristotle University of Thessaloniki, Thessaloniki, Greece
Clin Exp HEPATOL 2020; 6, 1: 63–64
Online publish date: 2020/02/17
View full text Get citation
 
PlumX metrics:
Dear Editor,
We have recently read with great interest the elegant paper authored by Piekarska et al. [1], who presented the results of the PRO-CARDIO-C study. The authors demonstrated in their large cohort that the relative frequency of positive anti-HCV (hepatitis C virus) antibodies and detectable HCV RNA in patients with coronary artery disease was not significantly different compared to that observed in patients hospitalized in a Dermatology Department (controls), despite the fact that the prevalence of chronic HCV infection was 5-fold higher compared to the general population [1].
Recently, Wen et al. published the results of their meta-analysis, demonstrating that HCV infection increases the risk of coronary artery disease (CAD) by 25% [risk ratio (RR): 1.25, 95% CI: 1.12-1.40] in cohort studies and the odds for CAD by 94% [odds ratio (OR): 1.58-2.38] in case-control and cross-sectional studies, establishing this close relationship [2]. Similar results were obtained by another meta-analysis in a total of 297,613 patients, confirming the association between HCV infection and cardio-cerebrovascular disease and its related mortality [3]. In a recent 13-year nationwide population-based study in Asia enrolling 31,943 patients either with chronic HBV (hepatitis B virus) or HCV infection it was shown that patients with HCV infection exhibit 38% greater risk of acute coronary syndrome (ACS) [hazard ratio (HR): 1.38, 95% CI: 1.02-1.85], compared to HCV patients, while they also exhibited a significant increase in the risk of all-cause mortality by 48%, acute ischemic stroke by 38% and composite arterial events (ACS, acute ischemic stroke, peripheral artery disease) by 29% [4]. However, data are contradictory concerning the angiographically proven atherosclerotic burden of CAD in patients with HCV infection compared to HCV negative control subjects [5, 6].
Thus, it seems undeniable that chronic HCV infection boosts the cardiovascular disease burden among the affected patients. The role of co-morbidities is of utmost importance, as it was recently observed in a US population-based study [7]. It would be interesting if Piekarska et al. could provide us with the patients’ co-morbidities, mainly diabetes mellitus, chronic kidney disease, hypertension and obesity, as they might have an impact on their results [1]. Another recently published retrospective analysis demonstrated that the presence of hepatic steatosis in a large cohort of patients...


View full text...
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.